- Home
- ORIC
as 06-17-2025 4:00pm EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 362.9M | IPO Year: | 2020 |
| Target Price: | $18.83 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.67 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | ORIC | Chief Financial Officer | Jun 6 '25 | Sell | $10.00 | 2,900 | $29,021.32 | 104,164 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
TipRanks
5 days ago
JPMorgan biotech/pharma analysts hold analyst/industry conference call
GlobeNewswire
11 days ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zacks
16 days ago
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
Zacks
20 days ago
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
MT Newswires
20 days ago
Top Premarket Gainers
Insider Monkey
20 days ago
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
MT Newswires
20 days ago
ORIC Reports Preliminary Efficacy in Metastatic Prostate Cancer Study; Starts $125 Million Private Placement
Compare ORIC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.